Advertisement

Jakafi Safe and Effective in Polycythemia Vera

The results from a Phase III clinical trial indicate that Jakafi (ruxolitinib) controlled hematocrit levels and reduced spleen size by 35% or more among patients with polycythemia vera.

 Cancer Connect

click me